SEC Form 4 · accession 0001209191-18-037311
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kamil Ali-Jackson
Officer — Chief Legal Officer
Period of report
Jun 11, 2018
Accepted (ET)
Jun 12, 2018 · 6:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 11, 2018 | S | 100 | $20.00 | D | 82,536 | D | |
| Common Stock | Jun 12, 2018 | S | 4,900 | $20.00 | D | 77,636 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018.